Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.

Authors :: Ross, Sarah J.
Revenko, Alexey S.
Hanson, Lyndsey L.
Ellston, Rebecca
Staniszewska, Anna
Whalley, Nicky
Pandey, Sanjay K.
Revill, Mitchell
Rooney, Claire
Buckett, Linda K.
Klein, Stephanie K.
Hudson, Kevin
Monia, Brett P.
Zinda, Michael
Blakey, David C.
Lyne, Paul D.
Macleod, A. Robert
Source :: Science Translational Medicine; 6/14/2017, Vol. 9 Issue 394, p1-13, 13p
Publication Year :: 2017
Abstract: The article discusses the efficacy of AZD4785 as treatment for KRAS-driven human cancers and tumors. It mentions that AZD4785 is a constrained ethyl-containing therapeutic antisense oligonucleotide (ASO) targeting KRAS mRNA. It notes that AZD4785 is an attractive treatment for KRAS mutant non-small cell lung cancer patients.

Subjects :: TUMOR genetics
CANCER treatment
GENE therapy
NON-small-cell lung carcinoma
MESSENGER RNA
DRUG efficacy
GENETICS

Full Text Access

Tools